A citation-based method for searching scientific literature


List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Tae Hyuk Kim, Young Joo Park, Jung Ah Lim, Hwa Young Ahn, Eun Kyung Lee, You Jin Lee, Kyung Won Kim, Seo Kyung Hahn, Yeo Kyu Youn, Kwang Hyun Kim,[...]. Cancer 2012
284
100


Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.
Haixia Guan, Meiju Ji, Rong Bao, Hongyu Yu, Yangang Wang, Peng Hou, Yong Zhang, Zhongyan Shan, Weiping Teng, Mingzhao Xing. J Clin Endocrinol Metab 2009
145
50

Management of low-risk differentiated thyroid cancer.
Ernest L Mazzaferri. Endocr Pract 2007
152
50


Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
50


Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.
Guoping He, Baojian Zhao, Xu Zhang, Rixiang Gong. Oncol Lett 2014
17
50

BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.
Samuel Enumah, Abbey Fingeret, Sareh Parangi, Dora Dias-Santagata, Peter M Sadow, Carrie C Lubitz. World J Surg 2020
6
50

BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
S Fraser, C Go, A Aniss, S Sidhu, L Delbridge, D Learoyd, R Clifton-Bligh, L Tacon, V Tsang, B Robinson,[...]. World J Surg 2016
21
50

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
379
50

Association of MicroRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer.
Daina Pamedytyte, Vaida Simanaviciene, Dalia Dauksiene, Enrika Leipute, Aurelija Zvirbliene, Valdas Sarauskas, Albertas Dauksa, Rasa Verkauskiene, Birute Zilaitiene. Biomolecules 2020
6
50

Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases.
Xiao-Min Yu, Yin Wan, Rebecca S Sippel, Herbert Chen. Ann Surg 2011
171
50


Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Huy Gia Vuong, Ahmed Ma Altibi, Uyen Np Duong, Hanh Tt Ngo, Thong Quang Pham, Hung Minh Tran, Naoki Oishi, Kunio Mochizuki, Tadao Nakazawa, Lewis Hassell,[...]. Tumour Biol 2017
22
50

Publication bias in clinical research.
P J Easterbrook, J A Berlin, R Gopalan, D R Matthews. Lancet 1991
50

Practical methods for incorporating summary time-to-event data into meta-analysis.
Jayne F Tierney, Lesley A Stewart, Davina Ghersi, Sarah Burdett, Matthew R Sydes. Trials 2007
50

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Steven I Sherman, R Michael Tuttle. Thyroid 2006
50

Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes.
Iwao Sugitani, Kazuhisa Toda, Keiko Yamada, Noriko Yamamoto, Motoko Ikenaga, Yoshihide Fujimoto. World J Surg 2010
289
50


Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang. Thyroid 2016
41
50

Sodium Selenite Enhanced the Anti-proliferative Effect of MEK-ERK Inhibitor in Thyroid Cancer Cells.
Jong Bin Kim, Eun Yeol Yang, Joohyun Woo, Hyungju Kwon, Woosung Lim, Byung-In Moon. In Vivo 2020
7
50

The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
Daniele Barbaro, Roberto Mario Incensati, Gabriele Materazzi, Giuseppe Boni, Mariano Grosso, Erica Panicucci, Paola Lapi, Cristina Pasquini, Paolo Miccoli. Endocrine 2014
37
50

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Yasuhiro Ito, Hiroshi Yoshida, Rie Maruo, Shinji Morita, Toru Takano, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda,[...]. Endocr J 2009
184
50

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Christopher Gouveia, Nhu Thuy Can, Alan Bostrom, James P Grenert, Annemieke van Zante, Lisa A Orloff. JAMA Otolaryngol Head Neck Surg 2013
70
50

Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification.
Xiaoxiong Gan, Fei Shen, Xingyan Deng, Jianhua Feng, Jiabao Lu, Wensong Cai, Lina Peng, Weipeng Zheng, Weijia Wang, Peidan Huang,[...]. Oncol Lett 2020
7
50

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
50

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Salvatore Ulisse, Enke Baldini, Salvatore Sorrenti, Susi Barollo, Natalie Prinzi, Antonio Catania, Angela Nesca, Lucio Gnessi, Maria R Pelizzo, Caterina Mian,[...]. Clin Endocrinol (Oxf) 2012
34
50


Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma.
Chan-Kwon Jung, So-Young Im, Yeo-Ju Kang, Hyoungnam Lee, Eun-Sun Jung, Chang-Suk Kang, Ja-Seong Bae, Yeong-Jin Choi. Thyroid 2012
42
50

Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
50

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
Lauren E Henke, John D Pfeifer, Changquing Ma, Stephanie M Perkins, Todd DeWees, Samir El-Mofty, Jeffrey F Moley, Brian Nussenbaum, Bruce H Haughey, Thomas J Baranski,[...]. Cancer Med 2015
41
50

Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Qing Zhang, Shao-zheng Liu, Qing Zhang, Yan-xing Guan, Qing-jie Chen, Qin-yao Zhu. Cell Physiol Biochem 2016
33
50

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.
Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo, Barbara Jarzab, Agnieszka Czarniecka,[...]. J Clin Oncol 2018
50
50

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Ralph P Tufano, Gilberto V Teixeira, Justin Bishop, Kathryn A Carson, Mingzhao Xing. Medicine (Baltimore) 2012
194
50

An observational trial for papillary thyroid microcarcinoma in Japanese patients.
Yasuhiro Ito, Akira Miyauchi, Hiroyuki Inoue, Mitsuhiro Fukushima, Minoru Kihara, Takuya Higashiyama, Chisato Tomoda, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya. World J Surg 2010
435
50

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017.
Seri Hong, Young-Joo Won, Young Ran Park, Kyu-Won Jung, Hyun-Joo Kong, Eun Sook Lee. Cancer Res Treat 2020
93
50

Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.
Bo Youn Cho, Hoon Sung Choi, Young Joo Park, Jung Ah Lim, Hwa Young Ahn, Eun Kyung Lee, Kyung Won Kim, Ka Hee Yi, June-Key Chung, Yeo-Kyu Youn,[...]. Thyroid 2013
110
50


Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park. Thyroid 2017
66
50

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
290
50

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer.
Alexander J Lin, Pamela Samson, Todd DeWees, Lauren Henke, Thomas Baranski, Julie Schwarz, John Pfeifer, Perry Grigsby, Stephanie Markovina. Cancer Med 2019
4
50

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Boban Stanojevic, Radan Dzodic, Vladimir Saenko, Zorka Milovanovic, Gordana Pupic, Ognjen Zivkovic, Ivan Markovic, Igor Djurisic, Marko Buta, Bogomir Dimitrijevic,[...]. Endocr J 2011
28
50

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
322
50

BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.
Yufei Chen, Peter M Sadow, Hyunsuk Suh, Kyu Eun Lee, June Young Choi, Yong Joon Suh, Tracy S Wang, Carrie C Lubitz. Thyroid 2016
47
50


BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.
Susi Barollo, Gianmaria Pennelli, Federica Vianello, Sara Watutantrige Fernando, Isabella Negro, Isabella Merante Boschin, Maria Rosa Pelizzo, Massimo Rugge, Franco Mantero, Davide Nacamulli,[...]. Eur J Endocrinol 2010
50
50

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy.
Yangbo Feng, Yanlu Xiong, Tianyun Qiao, Xiaofei Li, Lintao Jia, Yong Han. Cancer Med 2018
95
50

Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study.
Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim,[...]. Endocrinol Metab (Seoul) 2017
20
50

Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer.
Yanyan Gao, Fang Yang, Xiu-An Yang, Li Zhang, Huixin Yu, Xian Cheng, Shichen Xu, Jie Pan, Kun Wang, Peifeng Li. FEBS J 2019
10
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.